Could a bone drug ease pain in kids with rare inflammatory disease?
NCT ID NCT07668583
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug zoledronate can reduce pain in children aged 4 to 17 with chronic recurrent multifocal osteomyelitis (CRMO), a rare auto-inflammatory bone disease. The 30 participants have not responded to standard anti-inflammatory drugs. They will receive either zoledronate or a placebo by IV, and their pain levels will be tracked over 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- zoledronate (a bisphosphonate drug given by IV)
- What this could lead to
- If it works, this could point toward a new treatment option for children with hard-to-treat CRMO bone pain.
- What could go wrong
- This is a small early-phase trial with only 30 children, so results may not apply to everyone. The drug also has known risks like flu-like symptoms and kidney issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kremlin-Bicêtre Hospital
Le Kremlin-Bicêtre, Val De Marne, 94270, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.